In a 66-year-old woman with markedly elevated ferritin, high transferrin saturation, mildly elevated alkaline phosphatase, hyperlipidemia (total cholesterol 222 mg/dL, low‑density lipoprotein 129 mg/dL, triglycerides 182 mg/dL, high‑density lipoprotein 62 mg/dL) while taking atorvastatin, and mild eosinophilia, what management steps should be taken for these abnormal laboratory values?

Management of Abnormal Laboratory Values

Proceed immediately with fasting iron panel confirmation and HFE genetic testing for hemochromatosis given the persistently elevated transferrin saturation (65%, previously 50/44%) and ferritin (862 ng/mL), as this pattern strongly suggests hereditary hemochromatosis requiring definitive diagnosis and potential phlebotomy therapy. 1

Iron Overload Evaluation (Priority #1)

Your patient's iron studies demonstrate the classic biochemical signature of hemochromatosis:

• Transferrin saturation 65% (persistently >50% on prior testing)
• Ferritin 862 ng/mL (markedly elevated for a 66-year-old woman)
• Normal CBC (excluding anemia/reticulocytosis)

Immediate Next Steps:

1. Confirm with fasting iron panel: Repeat transferrin saturation and ferritin in the fasting state to eliminate postprandial variation 1

2. Order HFE genetic testing: The 2022 EASL guidelines explicitly recommend genetic testing for individuals with "persistently elevated transferrin saturation" and "high serum ferritin concentrations" 1. The combination of transferrin saturation >60% with ferritin >862 ng/mL has 95% accuracy for identifying clinically significant iron overload 2

3. Rule out secondary causes: While awaiting genetic results, verify:

   • No iron supplementation (already confirmed)
   • Alcohol intake history (can elevate ferritin)
   • Inflammatory conditions (though your patient's normal CBC and lack of elevated CRP argue against this)

Critical Distinction:

Dysmetabolic hyperferritinemia (associated with metabolic syndrome) typically presents with elevated ferritin but normal transferrin saturation (usually <45%) 3, 4. Your patient's transferrin saturation of 65% excludes this diagnosis and points toward true iron overload requiring treatment 1, 5.

If Hemochromatosis Confirmed:

• Initiate therapeutic phlebotomy: Target ferritin 50-100 ng/mL during maintenance phase 1
• Induction phase: Weekly phlebotomy (450-500 mL) until ferritin <50 ng/mL
• Monitor hemoglobin before each session; hold if <12 g/dL 1
• Dietary modifications: Limit red meat, avoid vitamin C supplements, restrict alcohol during iron depletion, avoid iron-fortified foods 1

Common pitfall: Do not dismiss elevated ferritin as "just metabolic syndrome" when transferrin saturation is persistently >50%. This delays diagnosis of hereditary hemochromatosis, which can prevent cirrhosis, diabetes, and cardiomyopathy if treated early 1.

---

Hyperlipidemia Management

Continue atorvastatin 10 mg but consider dose escalation to 20-40 mg to achieve better LDL-C control, as current therapy has not achieved optimal targets for a 66-year-old woman with cardiovascular risk factors 6, 7.

Current Lipid Profile Analysis:

• LDL-C 129 mg/dL: Above optimal target
• Triglycerides 182 mg/dL: Mildly elevated
• HDL-C 62 mg/dL: Protective
• Total cholesterol 222 mg/dL: Elevated

Rationale for Dose Increase:

The 2018 ACC/AHA guidelines support statin therapy for primary prevention in patients aged 66-75 years, with evidence showing similar relative risk reductions as younger patients 6. Your patient's current atorvastatin 10 mg dose is suboptimal given:

• LDL-C remains >100 mg/dL
• Patients requiring >45% LDL-C reduction may start at 40 mg daily 7
• Atorvastatin is well-tolerated in this age group 7

Action Plan:

• Increase to atorvastatin 20 mg daily (moderate intensity)
• Recheck lipid panel in 4-6 weeks 7
• Target LDL-C <100 mg/dL (ideally <70 mg/dL if additional risk factors present)
• Continue lifestyle modifications: Mediterranean diet, regular exercise, weight management

Important caveat: Monitor for statin-related myopathy given age >65 years is a risk factor 7. Instruct patient to report unexplained muscle pain, tenderness, or weakness.

---

Elevated Alkaline Phosphatase (141 U/L)

Order GGT and complete hepatic panel to differentiate hepatobiliary from bone source, particularly important given the concurrent iron overload evaluation 1.

Differential Considerations:

1. Hepatic iron overload: Hemochromatosis can cause mild transaminase and alkaline phosphatase elevations 1
2. Metabolic dysfunction-associated steatotic liver disease (MASLD): Common with hyperlipidemia
3. Bone disorders: Less likely given isolated alkaline phosphatase elevation
4. Statin effect: Atorvastatin can cause transaminase elevations but rarely isolated alkaline phosphatase 7

Next Steps:

• Order GGT: If elevated, confirms hepatobiliary source
• Review complete hepatic panel: AST, ALT, bilirubin, albumin
• Consider liver MRI with iron quantification: Serves dual purpose of assessing iron overload and evaluating for steatosis/fibrosis if hemochromatosis confirmed 1, 2

Critical point: If hemochromatosis is confirmed, the elevated alkaline phosphatase may reflect early hepatic iron deposition. Successful phlebotomy therapy often normalizes liver enzymes 1.

---

Mild Eosinophilia (Absolute Eosinophils 0.6 K/μL)

Monitor with repeat CBC in 3 months; no immediate intervention required unless symptoms develop.

Assessment:

• Mild elevation (normal <0.5 K/μL)
• No concerning symptoms mentioned
• Stable CBC otherwise

Monitoring Strategy:

• Repeat CBC in 3 months
• Investigate further only if:
  • Progressive increase
  • Absolute eosinophils >1.5 K/μL
  • Development of symptoms (rash, wheezing, abdominal pain)
  • Organ dysfunction

Common causes of mild eosinophilia: Allergies, medications (including statins rarely), parasitic infections. Given the mild degree and lack of symptoms, observation is appropriate.

---

Summary Algorithm

Week 1-2:

1. Fasting iron panel + HFE genetic testing
2. GGT + complete hepatic panel
3. Increase atorvastatin to 20 mg daily

Week 4-6:

• Review genetic testing results
• If HFE positive: Refer to hematology/hepatology for phlebotomy initiation
• Recheck lipid panel

Week 8-12:

• Liver MRI with iron quantification if hemochromatosis confirmed
• Repeat CBC to monitor eosinophilia
• Adjust atorvastatin based on lipid response

The iron overload evaluation takes absolute priority given the potential for preventing irreversible organ damage (cirrhosis, diabetes, cardiomyopathy) if hemochromatosis is diagnosed and treated early 1.